These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11514908)

  • 41. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group.
    Pediatrics; 1997 Jan; 99(1):93-9. PubMed ID: 8989345
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis.
    Robinson JL
    Curr Med Res Opin; 2009 Jul; 25(7):1631-2; author reply 1632-3. PubMed ID: 19480611
    [No Abstract]   [Full Text] [Related]  

  • 43. Infection by the respiratory syncytial virus in infants and young children at high risk.
    Bonnet D; Schmaltz AA; Feltes TF
    Cardiol Young; 2005 Jun; 15(3):256-65. PubMed ID: 15865827
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group.
    Subramanian KN; Weisman LE; Rhodes T; Ariagno R; Sánchez PJ; Steichen J; Givner LB; Jennings TL; Top FH; Carlin D; Connor E
    Pediatr Infect Dis J; 1998 Feb; 17(2):110-5. PubMed ID: 9493805
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods.
    Smith TRF; Schultheis K; Broderick KE
    Hum Vaccin Immunother; 2017 Nov; 13(11):2626-2629. PubMed ID: 28881156
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vaccine Induced Herd Immunity for Control of Respiratory Syncytial Virus Disease in a Low-Income Country Setting.
    Kinyanjui TM; House TA; Kiti MC; Cane PA; Nokes DJ; Medley GF
    PLoS One; 2015; 10(9):e0138018. PubMed ID: 26390032
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The future of respiratory syncytial virus vaccine development.
    Polack FP; Karron RA
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S65-73. PubMed ID: 14730272
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.
    Zhu Q; McLellan JS; Kallewaard NL; Ulbrandt ND; Palaszynski S; Zhang J; Moldt B; Khan A; Svabek C; McAuliffe JM; Wrapp D; Patel NK; Cook KE; Richter BWM; Ryan PC; Yuan AQ; Suzich JA
    Sci Transl Med; 2017 May; 9(388):. PubMed ID: 28469033
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ongoing developments in RSV prophylaxis: a clinician's analysis.
    Rezaee F; Linfield DT; Harford TJ; Piedimonte G
    Curr Opin Virol; 2017 Jun; 24():70-78. PubMed ID: 28500974
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevention of Respiratory Syncytial Virus Infection: From Vaccine to Antibody.
    Huang K; Wu H
    Microbiol Spectr; 2014 Aug; 2(4):AID-0014-2014. PubMed ID: 26104207
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current concepts on active immunization against respiratory syncytial virus for infants and young children.
    Kneyber MC; Kimpen JL
    Pediatr Infect Dis J; 2002 Jul; 21(7):685-96. PubMed ID: 12237605
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety of palivizumab in preterm infants 29 to 32 weeks' gestational age without chronic lung disease to prevent serious respiratory syncytial virus infection.
    Groothuis JR
    Eur J Clin Microbiol Infect Dis; 2003 Jul; 22(7):414-7. PubMed ID: 12827537
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advances in prevention of respiratory syncytial virus infections.
    Prober CG; Sullender WM
    J Pediatr; 1999 Nov; 135(5):546-58. PubMed ID: 10547241
    [No Abstract]   [Full Text] [Related]  

  • 56. Preventive and therapeutic strategies for respiratory syncytial virus infection.
    Vujovic O; Mills J
    Curr Opin Pharmacol; 2001 Oct; 1(5):497-503. PubMed ID: 11764776
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.
    Resch B
    Hum Vaccin Immunother; 2017 Sep; 13(9):2138-2149. PubMed ID: 28605249
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment and prevention options for respiratory syncytial virus infections.
    Levin MJ
    J Pediatr; 1994 May; 124(5 Pt 2):S22-7. PubMed ID: 8169754
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Respiratory syncytial virus prophylaxis--the story so far.
    Simoes EA; Groothuis JR
    Respir Med; 2002 Apr; 96 Suppl B():S15-24. PubMed ID: 11996400
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical experience with respiratory syncytial virus vaccines.
    Piedra PA
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S94-9. PubMed ID: 12671459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.